Chris Sale's Atlanta Redemption Is Real — and the Braves' Pitching Props Just Got Sharper

Chris Sale arrived in Atlanta as damaged goods. The Red Sox had cycled through Tommy John surgery, multiple fractures, and five seasons of underperformance. When Anthopoulos sent Vaughn Grissom to Boston in the 2023 offseason to acquire Sale, the baseball world had legitimate questions—Sale himself joked that his new general manager should have been drug tested for making such a move. The Braves were betting on health, resilience, and the possibility that a change of scenery could resurrect a pitcher who hadn't pitched like a star since 2018.

That bet has paid off in spectacular fashion. Sale won the Cy Young Award in 2024, his first All-Star selection since 2018, and is currently running a 1.89 ERA through 10 starts this season. The Braves, sitting at 35-16 with the best record in baseball through early May, have become the beneficiary of precisely the kind of late-career surge that defies conventional wisdom. Sale isn't just functional; he's elite. He's throwing with the command and stuff that made him a tier-one starter a decade ago, and he's doing it on a team that figures to be in October baseball.

What's driving the resurgence matters as much as the numbers. Sale has fundamentally altered his approach to the game—slowing down where he once rushed, practicing stillness where he once chased the next start. Physically, he credits the Braves' medical infrastructure and the absence of the pressure cooker that Boston had become. But the mechanical story is equally important: Sale's velocity is holding (sitting 96-98 on his fastball), his back-foot slider remains devastating, and his control has tightened. The strikeout rate is still elite (72 K in 62 IP), but it's the walk rate that matters for projection—just 14 walks in 62 frames tells you he's not just throwing hard, he's locating.

For bettors, the angle is straightforward but requires precision timing. Sale's 1.89 ERA is in genuine territory; the Braves' pitching depth makes their team total and first-five-inning props compelling when Sale takes the ball. His recent start against Miami (Wednesday) showcased the overpowering stuff that dominated in his prime—the kind of performance that shrinks offensive upside in real time. However, the market has already begun pricing in Sale's consistency. The question isn't whether he'll be good; it's whether you're getting plus value on unders in his starts, or whether the Braves' team total sits at a number that assumes Sale delivers exactly what he has been. Early in a season when the Braves are still building their sample and public perception hasn't fully caught up to their elite record, there's a narrow window to fade overs on games where Sale pitches and the opponent lacks a left-handed-heavy lineup capable of working counts against him.

The durability edge here is multi-game and season-long. Sale's health has already passed the test that broke him in Boston—his workload is now a full season, not a fragile experiment. The Braves' pitching infrastructure, combined with his mental recalibration, suggests this isn't a career-final spike but a sustainable third act. That's the difference between a one-game outlier and a pattern worth stacking. Sale's next start is the real prop play, not because of what he just did, but because the mechanisms that built his 1.89 ERA (control, stuff, health) are all on tape and all replicable.